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Abstract
Introduction Mounting evidence supports the existence of an important feedforward cycle between sleep and neurodegenera-
tion, wherein neurodegenerative diseases cause sleep and circadian abnormalities, which in turn exacerbate and accelerate 
neurodegeneration. If so, sleep therapies bear important potential to slow progression in these diseases.
Findings This cycle is challenging to study, as its bidirectional nature renders cause difficult to disentangle from effect. 
Likewise, well-controlled intervention studies are often impractical in the setting of established neurodegenerative disease. It 
is this that makes understanding sleep and circadian abnormalities in Huntington’s disease (HD) important: as a monogenic 
fully penetrant neurodegenerative condition presenting in midlife, it provides a rare opportunity to study sleep and circadian 
abnormalities longitudinally, prior to and throughout disease manifestation, and in the absence of confounds rendered by 
age and comorbidities. It also provides potential to trial sleep therapies at a preclinical or early disease stage. Moreover, its 
monogenic nature facilitates the development of transgenic animal models through which to run parallel pre-clinical studies. 
HD, therefore, provides a key model condition through which to gain new insights into the sleep-neurodegeneration interface.
Conclusions Here, we begin by summarising contemporary knowledge of sleep abnormalities in HD, and consider how well 
these parallel those of Alzheimer’s and Parkinson’s as more common neurodegenerative conditions. We then discuss what 
is currently known of the sleep-neurodegeneration cyclical relationship in HD. We conclude by outlining key directions of 
current and future investigation by which to advance the sleep-neurodegeneration field via studies in HD.
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 Introduction
The relationship between sleep and neurodegeneration is a 
key focus of contemporary neuroscience due to mounting 
evidence of an important feedforward cycle between the two.
In one arm of the cycle, neurodegenerative conditions 
beget sleep abnormalities. As a result of a combination 
of hypothalamic and brainstem dysfunction, along with a 
loss of long range connectivity, sleep becomes markedly 
impaired in 40–90% of patients with neurodegenerative con-
ditions [1–5]. This most commonly manifests as insomnia 
[4, 6, 7], but frequently also as circadian rhythm dysfunction 
[8] or other clinical sleep pathologies such as sleep apnoea 
or rapid eye movement sleep behaviour disorder (RBD) [4]. 
Such sleep disruption is a crucial determinant of a patient’s 
quality of life [9], falls risk [10], care giver burden [11] and 
progression to institutional care [12–15], yet is often not 
addressed in clinical care.
In the other arm, sleep impairment appears to exacer-
bate neurodegeneration. Sleep deprivation leads to cognitive 
deficits in domains including executive function, attention 
and processing speed, as well as affective disturbances such 
as impulsivity and emotional lability [16–20]. Sleep abnor-
malities hence almost certainly contribute to such features 
common in neurodegenerative conditions. However, increas-
ing evidence contends that abnormal sleep also drives the 
neurodegenerative pathology directly. For example, sleep 
 * Z. Voysey 
 zv214@cam.ac.uk
1 Department of Clinical Neurosciences, John Van Geest 
Centre for Brain Repair, University of Cambridge, 
Cambridge, UK
2 Faculty of Medicine and Health Sciences, University of East 
Anglia, Norwich, UK
3 Department of Clinical Neurosciences, John Van Geest 
Centre for Brain Repair, WT-MRC Cambridge Stem Cell 
Institute, University of Cambridge, Cambridge, UK
 Journal of Neurology
1 3
deprivation has been found to induce neuroinflammation 
[21] and aberrant protein homeostasis [22] implicated in 
neurodegenerative pathophysiology. Likewise, slow wave 
sleep plays a critical role in memory consolidation through 
synaptic modulation and the translation of hippocampal 
information to cortical engrams [23–25]. Sleep loss thus also 
likely contributes to the synaptic dysfunction and memory 
impairment of many neurodegenerative diseases. Most sig-
nificant of all has been the discovery of the glymphatic path-
way [26]: a glial-lined perivascular network of channels that 
allows cerebrospinal fluid to drain interstitial brain tissue of 
waste solutes. The predominant activity of this pathway in 
slow wave sleep [27, 28] has revealed the crucial role sleep 
plays in clearance of neurotoxic proteins. Both beta-amyloid 
and tau are now known to be cleared by glymphatic activity 
[29, 30], and sleep deprivation has been consequently been 
shown to cause marked, rapid increases in these pathogenic 
protein species [31, 32].
Such findings raise a further question: whether this del-
eterious feedforward cycle begins with neurodegeneration or 
abnormal sleep, and thus whether chronic sleep deprivation 
predisposes to neurodegeneration. In support of the latter, 
the sleep abnormalities associated with neurodegenerative 
disease consistently predate symptom onset [7], chronic 
sleep deprivation has been associated with an almost 50% 
increase in risk of dementia in large scale epidemiological 
studies [33, 34], and seminal studies in chronic sleep disrup-
tion among airline staff have suggested a causative relation-
ship [35, 36]. This is a question of vital importance to public 
health, given the endemic societal presence of chronic sleep 
poverty [37].
Understanding this cycle and treating sleep dysfunction 
may, therefore, present an important means by which to miti-
gate the severity and progression, or even onset, of neurode-
generative disease.
Yet, the bidirectional nature of the relationship between 
sleep and neurodegeneration makes it challenging to study, 
as cause is difficult to disentangle from effect. Moreover, 
studies are often weakened by age and comorbidity con-
founds typical in patients with neurodegenerative conditions, 
and well-controlled intervention studies are often impracti-
cal in the setting of established neurodegenerative disease.
It is this that places Huntington’s disease (HD) as a 
critical ‘gateway’ condition through which to advance our 
understanding of the sleep-neurodegeneration interface. 
HD is a fully penetrant, monogenic, autosomal-dominant 
inherited neurodegenerative condition, caused by a polyglu-
tamine expansion repeat in exon 1 of the huntingtin gene and 
characterised by a triad of motor, cognitive and psychiatric 
features typically manifesting between the ages of 35–50. 
Sleep abnormalities are highly prevalent [38], and, as in 
other neurodegenerative conditions, precede clinical onset of 
disease [39]. HD, therefore, provides a crucial opportunity 
to probe the sleep-neurodegeneration relationship longitu-
dinally, from prior to symptom onset, through the transi-
tion phase and into established disease, facilitating a precise 
interrogation of the strength, timing and directionality of 
interplay between specific sleep abnormalities and features 
of neurodegeneration. Moreover, it allows such studies to 
be undertaken in the absence of age and comorbidity con-
founds, and offers feasible opportunity to trial therapeutic 
interventions in prodromal and/or early stage cohorts. Fur-
thermore, its monogenic nature also facilitates the devel-
opment of transgenic animal models through which to run 
parallel pre-clinical studies. This is in stark contrast to more 
common conditions such as Alzheimer’s and Parkinson’s 
disease, where (1) typically a premorbid phase can only be 
recognised in hindsight, (2) a definite diagnosis is challeng-
ing to resolve with certainty during life, and (3) transgenic 
animal models cannot recapitulate the predominant, non-
Mendelian form of disease.
The study of sleep disturbance in HD, therefore, bears 
vital potential to inform the wider sleep-neurodegeneration 
field. Here, we begin by summarising contemporary knowl-
edge of sleep abnormalities in HD, and consider how well 
these parallel those of Alzheimer’s and Parkinson’s as more 
common neurodegenerative conditions. We then discuss 
what is currently known of the sleep-neurodegeneration 
cyclical relationship in HD, and the evidence as to how HD 
causes sleep abnormalities, and whether sleep abnormalities 
drive HD pathophysiology. We conclude by outlining key 
directions of current and future investigation by which to 
advance the sleep-neurodegeneration field via studies in HD.
Sleep and circadian abnormalities 
in Huntington’s disease: evidence to date
Clinical sleep pathology
Epidemiological analysis has suggested that clinical sleep 
pathology is present in as many as 88% of patients with 
manifest HD [40]. However, such observations are based 
on subjective patient reports, and studies comparing these 
to formal sleep study assessments have revealed prominent 
discrepancy, both with respect to over- and under-estimation 
[41, 42]. It is thus judicious to limit any review only to those 
studies incorporating objective sleep assessments when con-
sidering clinical sleep pathologies characterising HD. Of 
these, the consensus emergent from the literature is of two 
prominent pathologies: insomnia [43, 44] and abnormal 
motor activity during the sleep period [43, 45–48]. There 
is controversy as to what this motor activity constitutes [49, 
50]: two studies have identified evidence of frequent peri-
odic limb movements during sleep [43, 44], but in addition, 
several studies have identified complex, high amplitude and 
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non-stereotyped movements that occur subsequent to arous-
als to wakefulness [46–48]. These have been interpreted 
as chorea [47, 48], repetitive ballistic movements [47], or 
voluntary repositioning movements rendered atypical by 
underlying HD-related hypotonia and incoordination [46]. 
RBD does not appear to be prevalent [43, 44]; nor does sleep 
disordered breathing [43, 51, 52] with the exception per-
haps of late stage disease [53]. With respect to excessive 
daytime somnolence, two studies have identified shortened 
latencies to sleep on objective daytime nap tests [39, 44] 
but the majority of studies have found this to be clinically 
asymptomatic [43, 44, 54].
In this respect, HD fails to closely recapitulate the sleep 
abnormalities of other more common neurodegenerative 
conditions. For example, while insomnia is a common 
denominator across the spectrum of neurodegeneration, Alz-
heimer’s disease is typified by high rates of sleep disordered 
breathing [55], while Parkinson’s disease is characterised by 
prominent RBD and excessive daytime somnolence [56]. 
Nonetheless, such discrepancies are arguably themselves of 
value, informing how differing patterns and mechanisms of 
neurodegeneration give rise to divergent sleep pathologies.
Sleep architecture abnormalities
Sleep is divided into stages by encephalography (EEG), 
muscle tone and eye movement hallmarks identifiable dur-
ing polysomnography (sleep studies; PSG). Healthy adult 
sleep is highly structured, characterised by a transition 
through progressively deeper non-rapid eye movement sleep 
(NREM) stages known as N1, N2 and N3/slow wave sleep, 
followed by rapid eye movement (REM) sleep. This cycle 
repeats four to five times per night. Aberrations of this struc-
ture, referred to as sleep architecture, are highly prevalent 
in neurodegenerative disease, even in individuals without 
clinical sleep pathology [42].
There have been numerous clinical PSG studies in HD 
[39, 42–44, 46, 57], alongside a number in animal models 
[58, 59]. There is marked variability among these studies 
as to the sleep architecture abnormalities that are reported. 
The reasons for this are likely manifold: a lack of genetic 
diagnosis in early studies, heterogeneity of clinical stage, 
medication confounds, use of single night PSG which is vul-
nerable to habituation artefact, and discrepancy in the PSG 
features being studied.
However, a recent meta-analysis [60] of these studies 
has helped to address this. This identified the consistent 
sleep architecture abnormalities of HD as being those of 
reduced sleep efficiency, increased time awake after sleep 
onset, delayed REM sleep onset, and an increased pro-
portion of time spent in the lightest stage of sleep (N1) 
versus a reduction of time spent in slow wave sleep and 
REM sleep. Of note, this shares striking similarities with 
the abnormalities found in Alzheimer’s and Parkinson’s 
disease [7], supporting the possible validity of HD as a 
model for more common conditions with respect to sleep 
architecture changes.
Cross-sectional studies of premanifest and early stage 
HD patients have revealed such sleep architecture abnor-
malities to be present many years prior to manifest disease, 
and to worsen with approaching manifest disease onset 
[39, 42, 44]. Among the subsequent manifest HD popula-
tion, sleep abnormalities appear to continue to progress 
in parallel with increasing disease severity [44, 57, 60]. 
Again this mirrors findings in Alzheimer’s and Parkinson’s 
[61, 62].
Some studies have also assessed for the presence of sleep 
fragmentation, rather than simply the total time spent in 
each sleep stage [39]. This has revealed that fragmentation 
appears to be an important component of HD sleep architec-
tural disturbance, including in the premanifest phase. Once 
again this parallels findings in Alzheimer’s and Parkinson’s, 
where sleep fragmentation in particular has been identified 
as a feature of both premonitory and established disease 
[62–66].
Transgenic HD mouse models [58, 59] have corroborated 
these findings in a number of notable ways, demonstrating 
increased sleep fragmentation and a loss of slow wave sleep, 
and progression of sleep abnormalities with disease severity. 
However, in contrast to human studies, they demonstrate an 
increase in REM phase. The latter likely reflects imperfect 
congruity between human and rodent sleep, and between 
murine HD models (with much longer polyglutamine repeat 
length and the use of differing promoters) versus human 
disease.
A handful of studies have employed quantitative EEG: 
analysis of the relative frequency composition of PSG EEG 
recordings. Transgenic HD mouse models have demon-
strated an increase in gamma frequency content in NREM 
sleep, and a shift of REM peak frequency from 7 to 6 Hz 
[58]. Echoing this, human studies have indicated an increase 
in gamma content of NREM sleep, and a loss of theta range 
activity in REM and NREM sleep [39]. Similarly, a recent 
study employing a technique to localise quantitative EEG 
changes has also indicated theta component loss: in motor/
premotor areas in NREM, and in limbic regions in REM 
[41]. Evidence is as yet too sparse to place weight on these 
findings, but it is of note that theta range activity in sleep 
has been implicated in neural restoration [67], and a gain 
in gamma frequencies has been recognised in both schizo-
phrenia and drug-induced psychosis, including in sleep [68].
There is thus relatively comprehensive evidence for sleep 
architecture changes in HD. Yet, the most informative study 
has yet to be performed: that of a longitudinal study of these 
abnormalities in an HD patient cohort, initiated in the pre-
manifest phase and tracked against clinical features.
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Circadian abnormalities
Circadian abnormalities are also prevalent in HD, with avail-
able evidence favouring a loss of circadian amplitude over a 
defined phase shift. For example, transgenic animal models 
of HD have demonstrated progressive dampening of circa-
dian rhythmicity, as indicated by diminished diurnal patterns 
of activity, heart rate variability and body temperature [58, 
69, 70]. Clinical studies have supported this, for example 
demonstrating loss of circadian blood pressure variability 
[71] and disrupted rest-activity patterns without overt phase 
shift [59]. Such blunting of circadian rhythm is shared by 
Alzheimer’s and Parkinson’s disease, although phase shift 
appears to also be present in Alzheimer’s [8].
Three cross-sectional studies have examined circadian 
melatonin release in HD patients. These have failed to cor-
roborate one another, reporting mixed results regarding 
phase shift, reduction or increased temporal spread in mela-
tonin secretion [54, 72, 73]. This lack of consensus owes as 
much to the paucity of studies as it does to the low number 
and heterogeneity of participants within them: a large-scale 
and longitudinal study of melatonin in an HD cohort is, 
therefore, needed.
How Huntington’s disease causes sleep 
abnormalities
HD neuropathology is known to affect the hypothalamus 
[74, 75]. Since this is the seat of both the body’s master 
circadian clock, the suprachiasmatic nucleus, and orexin 
neurons responsible for gating sleep/wake states, this is 
postulated as a key mechanism by which HD brings about 
sleep and circadian dysfunction. In support of this, abnor-
malities in orexinergic function have been observed [76, 
77] and altered neuronal firing rates have been identified 
in the suprachiasmatic nucleus in HD animal models [78]. 
Nonetheless, the applicability of such findings to human dis-
ease is questionable. For example, there is poor overlap of 
hypothalamic abnormalities in HD pre-clinical and clinical 
studies [79], and clinical imaging studies of hypothalamic 
changes have shown little correlation with sleep/circadian 
dysfunction [80].
HD neuropathology is also proposed to bring about 
sleep dysfunction via influence in other brain regions. For 
example, HD is recognised to lead to atrophy in brainstem 
structures such as the locus coeruleus that gate transition 
between sleep stages [81, 82]. Likewise, healthy slow wave 
sleep requires both local cortical and brain-wide synchrony 
of neuronal oscillatory activity. It may, therefore, also be that 
the widespread cortical pathology of HD, which affects con-
nectivity even from presymptomatic stages [83], accounts 
for deficits in slow wave sleep. Moreover, recent evidence 
has identified a possible role of the striatum in governing 
arousability during sleep, and the generation of periodic 
limb movements [43, 84, 85]. As the striatum is a major 
early and enduring site of HD pathology, this raises a further 
possible link between HD pathology and sleep disruption. 
Direct evidence to support such hypotheses is, however, 
lacking.
Preclinical models have sought to explain circadian 
disruption in HD through the effect of HD pathology on 
clock genes. Clock genes are those that interact via intricate 
feedback loops generating cycles of gene expression with 
a period of approximately twenty-fours, thereby providing 
cellular circadian rhythm. These are expressed in the supra-
chiasmatic nucleus to provide master, coordinating circa-
dian periodicity, but also function in most nucleated cells 
to provide cell-autonomous circadian rhythm that is then 
‘tuned’ by the master clock and other peripheral cues [86]. 
Studies of clock genes in transgenic HD mice have almost 
invariably found evidence of aberrant clock gene expression 
in vivo, in sites ranging from the suprachiasmatic nucleus to 
the neocortex to liver [59, 69, 87]. However, significantly, 
these aberrations resolve upon ex vivo study [87, 88]. This 
suggests that circadian dysfunction in HD is driven by 
system-wide influences on clock gene expression, such as 
altered melatonin, cortisol or circadian behaviour rhythms, 
rather than the direct influence of mutant huntingtin pro-
tein on intrinsic clock gene function at a cellular level. In 
support of this, a transgenic sheep model of HD found that 
circadian behaviour abnormalities dissipated when animals 
were housed with controls providing normal circadian cue-
ing [89], suggesting that circadian dysfunction is driven 
more by altered extrinsic zeitgebers than by intrinsic clock 
gene expression alterations. Nonetheless, such findings are 
again hypothetical, as there have so far not been any studies 
of clock genes in HD patients.
Evidence linking Huntington’s sleep abnormalities 
to disease exacerbation
Most notable of all is the evidence that sleep abnormalities 
exacerbate HD pathology.
A number of pre-clinical intervention studies have 
emerged over recent years suggesting that treating sleep 
abnormalities may improve clinical outcomes in HD. The 
earliest of these, employing alprazolam in a transgenic 
HD murine model, indicated that pharmacological imposi-
tion of sleep could improve cognitive outcome, independ-
ent of anxiolytic effect [88]. A further study by the same 
group demonstrated that behavioural circadian interven-
tion, mediated by housing animals with intact circadian 
behaviours, had the same effect [90]. A more recent study 
of circadian re-entrainment, delivered via blue light ther-
apy in transgenic HD mice, also led to improvements in 
locomotor activity rhythms and motor performance [91]. 
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However, sleep timing or quantity did not alter, and there-
fore, it is questionable whether the benefit was secondary 
to the alerting influence of light therapy rather than its 
impact upon circadian rhythm or sleep quality. Nonethe-
less, a further study of light-mediated circadian entrain-
ment in transgenic HD mice has demonstrated improved 
survival rates [92], and another employing timed feeding 
as a circadian cue has also reported improved motor out-
comes [93]. The most recent pre-clinical study of sleep 
therapy in HD, using an orexin antagonist, has also dem-
onstrated benefit to cognitive outcome [94].
Such studies are of great significance, as they add 
weight to the notion that sleep abnormalities exacerbate 
neurodegeneration, and suggest that sleep therapies may, 
therefore, present a viable means by which to slow dis-
ease progression. Given that we currently have no proven 
disease-modifying treatments for HD, this is of salient 
importance.
Nevertheless, none of these studies has yet evaluated 
whether the interventions modified HD outcomes through 
changes at a pathophysiological level, or whether these 
were mediated solely through symptomatic gains. A defini-
tive study of whether sleep deprivation promotes accumu-
lation or spread of mutant huntingtin protein, for example, 
is lacking.
Moreover, to date, there has been no retrospective and 
only one prospective translational sleep therapy interven-
tion study in HD. This comprised a 9 month pilot study of 
a multidisciplinary intervention, including exercise, cogni-
tive training, sleep hygiene measures, nutritional guidance 
and socialisation, in a cohort of sixteen premanifest HD 
patients [95]. This intervention was well appointed, given 
that such multi-component therapies carry some of the 
greatest evidence for efficacy and safety in treating sleep 
in neurodegenerative conditions [96–99]. Gains in REM 
sleep were demonstrated, while improvements in slow 
wave sleep, HD-related structural brain changes and cog-
nitive outcomes were not observed. While disappointing, 
it should be noted that the study was limited in a number 
of ways. Besides its small sample size and lack of control 
group, pre and post intervention PSG was of one-night 
duration and, therefore, liable to habituation artefact, and 
cognitive improvement was assessed via only one cogni-
tive test: the Hopkins Verbal Learning Test of memory 
consolidation. There is, therefore, a prescient need for 
larger, better controlled and more detailed clinical stud-
ies of sleep therapy intervention in HD. These would be 
enhanced further by the inclusion of biomarkers of disease 
activity as endpoints. There is growing contemporary evi-
dence for the validity of serum neurofilament light chain, 
and cerebrospinal tau and mutant huntingtin, in this regard 
[100, 101], making this a natural line of investigation yet 
to be pursued.
Conclusions and future directions
Though HD differs from more common conditions like 
Alzheimer’s and Parkinson’s with respect to prevalent clin-
ical sleep pathology, there are important parallels evident 
in relation to the timing and nature of sleep architecture 
and circadian disturbances. This suggests that HD consti-
tutes a valid model condition, while offering important 
opportunities not afforded by other neurodegenerative 
conditions. As such, Huntington’s disease is well-placed 
to provide key new insights into the relationship between 
sleep and neurodegeneration.
Great advances have been made over the last few years to 
exploit this potential, in particular in the form of pre-clinical 
sleep intervention studies examining the link between sleep 
abnormalities and disease exacerbation. The fact that these 
have demonstrated improved clinical outcomes in response 
to treating sleep dysfunction raises important hopes both for 
HD and the wider neurodegeneration field.
However, a number of salient gaps in the literature 
remain:
Firstly, there has yet to be a longitudinal clinical study 
of sleep abnormalities versus clinical outcomes in Hunting-
ton’s disease, initiated from the premanifest phase. This is 
a prominent omission, since this is the key opportunity fea-
sible in HD that is not possible in other neurodegenerative 
conditions. Such a study would enable delineation of the 
strength and timing of associations between specific sleep 
abnormalities and features of neurodegeneration, helping to 
unravel the ‘chicken and egg’ of the sleep-neurodegeneration 
relationship. This is a study we are currently completing.
Secondly, there has yet to be a study of clock gene 
expression in HD patients. The most valuable study would 
be one designed to differentiate aberrant expression due 
to altered cell-extrinsic cues from that caused by intrinsic 
clock dysfunction. This is needed to translate the findings 
of pre-clinical studies, and to resolve the source of circa-
dian dysfunction to in turn guide therapeutic strategies. 
Akin to this, more detailed studies of the mechanisms by 
which HD effects sleep architecture abnormalities would 
also help guide therapy trials.
Thirdly, studies evaluating the effect of sleep distur-
bance on HD disease activity, rather than solely clinical 
features, are currently lacking. This could be achieved, 
for example, by subjecting transgenic HD mice to sleep 
deprivation or sleep therapy, and assessing the effect on 
central nervous system mutant huntingtin accumulation. 
This is vital to understanding whether sleep abnormalities 
exacerbate HD disease burden on a pathophysiological or 
a solely symptomatic level.
Finally, and most importantly, there is a pressing need 
for robust sleep intervention studies in HD cohorts, to 
assess whether the promising findings of pre-clinical 
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studies translate to patients. Current evidence does not 
favour the use of traditional sedating agents as sleep inter-
ventions in neurodegeneration: studies of antidepressants, 
antihistamines and antipsychotics in patients with mixed 
dementia, Alzheimer’s and Parkinson’s, for example, 
have suggested that deleterious effects outweigh benefit 
when used as sleep agents [102–104]. Likewise, there is 
presently a lack of cogent evidence suggesting signifi-
cant benefit from modafinil [105, 106] or melatonin [107, 
108]. However, in addition to the described behavioural 
interventions [109], sodium oxybate [110, 111], orexin 
antagonists [112, 113] and devices facilitating acoustic 
augmentation of slow wave sleep [114] are all demonstrat-
ing potential to improve both sleep and cognitive outcomes 
in neurodegenerative cohorts, but have yet to be trialled 
in an HD population. Again, the most valuable studies 
employing such interventions would be those incorporat-
ing biomarkers of disease activity as endpoints, to inter-
rogate effects on clinical features versus pathophysiology.
We believe that such studies represent a research priority, 
both for Huntington’s disease and for informing the wider 
sleep-neurodegeneration field.
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